SSS. S. Sterlikova

S. S. Sterlikova

*This is an algorithmically generated author record based on publicly available information.

S. S. Sterlikova has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combined Use of a Fluoroquinolone and Bedaquiline in Children with Multidrug-Resistant Respiratory Tuberculosis from the Standpoint of Cardiotoxicity

    by M. F. Gubkina, Yu. Yu. Khokhlova, I. Yu. Petrakova, N. V. Yukhimenko, S. S. Sterlikova

    The objective: to evaluate the effect of combined use of a fluoroquinolone and bedaquiline on the QT interval length when added to chemotherapy regimens in children with multidrug-resistant respiratory tuberculosis. Subjects and Methods. A retrospective, selective comparative study (2018-2022) was conducted among two groups of children aged 6-12 years with multidrug-resistant respiratory tuberculosis: Main Group (MG) consisted of 13 children who received two drugs with a cardiotoxic effect (bedaquiline and a fluoroquinolone) in their chemotherapy regimen; while 13 children who received a chemotherapy regimen containing a fluoroquinolone only were included in Comparison Group (CG). During the study, a standard ECG was performed assessing the length of the QT с interval. Results. Prolongation of the QT с interval was a frequent (84.6%) adverse reaction (AR) in children from MG and it was observed statistically significantly less frequently (15.4%) in CG, p с interval prolongation was also reported significantly more frequently in MD versus GS: 36 (23.8%) cases out of 151 examinations and 6 (4.2%) out of 144 examinations, respectively, χ2=23.367, p ≤0.001. The range of deviations of the QT с interval from the reference value (440 ms) did not exceed 460 ms in MG in 28/36 (77.8%) episodes, in CG – in 6/6 (100%) episodes. Prolongation of the QT с interval from 461 ms and more was recorded only in MG – 8/36 (22.2%). And only 1/13 (7.7%) patient from MG had a prolongation of the QT с interval to 512 ms. In no case the prolongation of the QT с interval was accompanied by clinical symptoms; no electrolyte disturbances, changes in liver or kidney function, or paroxysmal rhythm disturbances were observed.

  • Open Access

    The Effectiveness of Delamanid in Short-Course Chemotherapy Regimens for Drug-Resistant Tuberculosis in Children and Adolescents

    by L. V. Panova, E. S. Ovsyankina, I. Yu. Petrakova, E. A. Krushinskaya, F. A. Poluektova, V. V. Bereznitskaya, S. S. Sterlikova, Yu. Yu. Khokhlova, V. V. Lopatin

    Background . The development of short, safe, and effective chemotherapy regimens for drug-resistant tuberculosis in children and adolescents — based on the introduction of new drugs — remains a pressing issue. The aim of the study was to evaluate the effectiveness and safety of short-course chemotherapy regimens incorporating delamanid (Dlm) in children and adolescents with tuberculosis caused by multidrug-resistant, pre-extensively drug-resistant, or extensively drug-resistant (MDR/pre-XDR/XDR) strains. Materials and Methods . A prospective, open-label, non-comparative study has been conducted since March 2022. The study enrolled 37 patients (aged 2–17 years) with various forms of respiratory tuberculosis who received Dlm in combination with a standard regimen consisting of at least three drugs. The primary efficacy analysis was performed upon completion of the main course of chemotherapy, involving an assessment of treatment outcomes; the secondary analysis consisted of a follow-up visit at one year to monitor for tuberculosis recurrence. The assessment of Dlm tolerability was based on: cardiotoxic reactions (ECG monitoring); neuropsychiatric reactions (patient interviews, observation of behaviour and sleep). Results . The treatment outcome recorded was «clinically cured» for 100% of patients across all age groups. Short-course chemotherapy regimens were administered to 83.0% (29/35) of patients (70.4–95.3%, 95% CI). Of the 29 patients treated with short-course regimens: 3 received a 6-month regimen, 9 received a 9-month regimen, and 17 received a 12-month regimen. Follow-up was conducted one year after the completion of shortcourse treatment regimens in 16 patients; no relapses were detected. An association between the administration of Dlm and the development of adverse reactions was established in 8% (3/37) of cases — specifically, neuropsychiatric adverse reactions. Conclusion . The use of Dlm in combination with other drugs within short-course chemotherapy regimens for tuberculosis — specifically, cases involving MDR, pre-XDR, or XDR Mycobacterium tuberculosis — demonstrates a high success rate when administered as part of a comprehensive treatment strategy.

  • Open Access

    The Impact of Chemotherapy for Drug-Resistant Respiratory Tuberculosis on the Composition of Fecal Microbiota in Children

    by N. V. Yukhimenko, S. S. Sterlikova, M. F. Gubkina, S. I. Kayukova, A. E. Donnikov

    The objective: to study the species and quantitative composition of fecal microbiota in children undergoing chemotherapy for drug-resistant respiratory tuberculosis. Subjects and Methods. The study included 17 children from 2 to 12 years old with respiratory tuberculosis who received treatment for drug-resistant respiratory tuberculosis from 2022 to 2024 at Central Tuberculosis Research Institute. Fecal microbiota was tested by real-time PCR using the ENTEROFLOR® Children reagent kit at the following time points: before the start of chemotherapy, after 2 and 4 months of chemotherapy. Results. The most pronounced disturbances in the intestinal microbiocenosis among representatives of normobiota were noted after 2 months of chemotherapy; by 4 months, those parameters did not deteriorate either in quantitative terms or frequency of deviations from reference values: for representatives of the phylum Actinomycetota (Actinobacteria) – in Bifidobacterium spp. and Coriobacteriia , for representatives of the phylum Bacteroidota (Bacteroidetes) – in Butyricimonas spp. , Parabacteroides spp., Prevotella spp. Changes in the composition of normobiota were associated with the elevated proportion of opportunistic microbiota by 2 months and persistence of these values by 4 months of chemotherapy. Representatives of pathogenic microbiota, which were not present before chemotherapy, appeared by 2 months of chemotherapy with the following frequency: Streptococcus agalactiae – in 35.3% of cases, Clostridioides difficile , with the toxigenic genes cdtA and cdtB – in 58.9%, and increasing to 71.5% by 4 months of chemotherapy. Conclusion. Treatment with chemotherapy regimens for drug-resistant tuberculosis has a statistically significant negative impact on intestinal microbiota in children: the proportion of normobiota decreases, the proportion of opportunistic microbiota increases, and pathogenic microbiota develops.

  • Open Access

    The State of Vaginal Microbiota in Girls Aged 2-13 Years with Respiratory Tuberculosis during Chemotherapy

    by S. S. Sterlikova, N. V. Yukhimenko, S. I. Kayukova, M. F. Gubkina, E. V. Uvarova, A. V. Kazakova, A. E. Donnikov

    The objective : to study the species and quantitative composition of vaginal microbiota in the girls aged 2-13 years, ill with respiratory tuberculosis during chemotherapy. Subject and Methods : 80 girls aged 2-13 years were enrolled in the study: Group 1 (21 patients) included girls ill with respiratory tuberculosis at different stages of anti-tuberculosis therapy Group 2 (59 patients) included girls belonging to Health Groups 1 and 2, not registered in TB services. Vaginal microbiota was tested once using microscopy and real-time PCR (FEMOFLOR®16 reagent kit, DNA-Technology LLC, Russia). Results of the vaginal microbiota testing were assessed taking into account the Tanner stages for girls. Results . In girls from Group 1, vaginal dysbiosis was recorded in 90.5% of cases (with Tanner I – 100% of cases, Tanner II-III – 88.9%, Tanner IV – 85.7%) and was associated in 66.7% of cases with candidal vulvovaginitis (with Tanner I – 100% of cases, Tanner II-III – 55.6%, Tanner IV – 57.1%). Vaginal dysbiosis occurred with complaints in 19.0% of cases and clinical manifestations in 71.4% of cases. Specific features of the vaginal microbiota composition in girls of Group 1 were identified based on the frequency of detection and quantitative content of symbionts. The molecular genetic testing made it possible to increase the efficiency of diagnosing candidal vulvovaginitis to 66.7%, versus 28.6% in microscopic examination of scrapings from the mucous membrane of vulva and vaginal vestibule with a predominance of the species Candida glabrata (42.8%). Conclusion . The girls ill with tuberculosis and receiving anti-tuberculosis therapy suffer from significant changes in the species and quantitative composition of the vaginal microbiota.

  • On the Effectiveness of Bedaquiline in Chemotherapy Regimens for Drug-Resistant Tuberculosis in Children with Various Body Weights

    by L. V. Panova, I. Yu. Petrakova, S. S. Sterlikova, T. G. Smirnova

    Background. WHO experts emphasize that the use of bedaquiline in children is conditional, supported by limited evidence and a very low certainty of recommendations. The aim of the study was to evaluate the effectiveness of bedaquiline in chemotherapy regimens for drug-resistant tuberculosis in children depending on body weight. Methods. A retrospective study included 27 children (6–12 years) with confirmed or probable (reliable contact with a patient) MDR/pre-XDR tuberculosis. Group I included 11 children weighing 30 kg, Group II included 16 children weighing 30 kg. The bedaquiline dose was 200 mg daily for the first 2 weeks (saturation phase), then 100 mg 3 times a week for 22 weeks (maintenance phase). The following were assessed: the time to cessation of bacterial excretion and radiographic dynamics (closure of decay cavities; resorption of infiltrative, focal, and pleural changes). At the end of chemotherapy, the treatment outcomes were assessed; follow-up examinations were conducted after 6 months and after 1 year. Results. Within 3 months of chemotherapy, abacillation was achieved in all 3 patients with MBT. Lung cavity closure was achieved in 2 patients out of 4. Clinical cure was achieved in 100% of patients in the comparison groups (p 0.05). No recurrences were detected. Conclusion. This study, based on real-world clinical practice of using bedaquiline in children with tuberculosis aged 6–12 years, demonstrated the feasibility of effective use of the pediatric dosage of the drug in patients weighing 30 kg or more.

  • Open Access

    Cases of Mycobacteriosis with Intrathoracic Lymph Node Involvement in Infants

    by M. F. Gubkina, S. S. Sterlikova, I. Yu. Petrakova, N. V. Yukhimenko, Yu. Yu. Khokhlova, Ю. Ю. Хохлова

    The article describes two clinical cases of mycobacteriosis with intrathoracic lymph node involvement in infants. In both cases, the disease occurred in infancy and tuberculosis was initially diagnosed. The protracted disease required surgical treatment. The histological signs were consistent with granulomatous inflammation with caseous necrosis. The diagnosis was established by the detection of M. avium DNA in the surgical specimens. No underlying diseases accompanied by immunosuppression were found in the infants. Only anti-tuberculosis drugs were used for treatment. The disease was successfully cured; during follow-up examinations (one year after the treatment completion), there was no evidence of the disease relapse.


  • Open Access

    Gut Microbiota and Pulmonary Tuberculosis (Literature Review)

    by N. V. Yukhimenko, S. S. Sterlikova, M. F. Gubkina, S. I. Kayukova

    The review analyzes 69 publications, of which 45 are devoted to studying gut microbiota in tuberculosis patients. The review presents data on the effect of gut microbiota disorders on the development of tuberculosis, severity and relapse rate. It covers the issues of changes in gut microbiota composition during anti-tuberculosis therapy and the effect of their management with probiotics on the tolerability of anti-tuberculosis therapy and effectiveness of treatment, including children.

  • Open Access

    The vitamin D status and the levels of β1- and β2-defensins in children and adolescents with different forms of pulmonary TB

    by L. V. Panova, M. M. Averbakh, E. S. Ovsуankina, I. N. Zakharova, A. V. Karasev, Yu. Yu. Khokhlova, S. S. Sterlikova, Ю. Ю. Хохлова

    Introduction. The basic research demonstrated an important role of vitamin D in strengthening the immune response to Mycobacterium tuberculosis and proved its effect on the production of antimicrobial peptides. However, the correlation between the levels of vitamin D and defensins (β1 and β2) in children and adolescents with different forms of pulmonary TB was not studied.Aim. To study the correlation between the levels of vitamin D and β1- and β2-defensins in children and adolescents with different forms of pulmonary TB.Materials and methods. We carried out a prospective study of 75 patients with pulmonary TB aged 2–17 years (52 new cases and 23 retreatment cases) in 2021–2023. The levels of 25(OH)D and β1- and β2-defensins were determined at admission to hospital.Results. Out of 75 patients 2.7% had adequate levels of vitamin D (more than 30 ng/mL), 13.3% had insufficient levels of vitamin D (20 to 30 ng/mL), 34.7% had deficient levels of vitamin D (10 to 20 ng/mL), and 49.3% had severe deficiency of vitamin D (less than 10 ng/mL). We established a direct correlation between 25(OH)D and β1-defensin levels (p = 0.004766) and lack of correlation between 25(OH)D and β2-defensin levels. We discovered significant differences in the levels of 25(ОН)D and β1-defensin between new and retreatment cases: 13.10 ± 1.04 ng/mL and 8.74 ± 1.07 ng/mL (p = 0.004644) and 6.66 ± 0.79 ng/mL and 4.0 ± 0.85 ng/mL (p = 0.024816), respectively.Conclusion. The differences in the levels of calcidiol and β1-defensin between new and retreatment cases witness an impaired function of one of the innate non-specific immunity components during long-lasting advanced pulmonary TB in children and adolescents.


  • Open Access

    Cellular and humoral responses to SARS-CoV-2 (omicron variant) in children and adolescents with pulmonary tuberculosis

    by M.M. Averbakh, L.V. Panova, E.S. Ovsyankina, A.E. Ergeshov, T.G. Smirnova, E.A. Kiseleva, Yu.YU. Khokhlova, S.S. Sterlikova

    Клеточный и гуморальный ответ на SARS-CoV-2 (штамм омикрон) у детей и подростков с туберкулезом органов дыхания


  • Open Access

    Differentiated Approaches to the Choice of Timing of Surgical Treatment for Intrathoracic Lymph Node Tuberculosis in Children during Increasing Incidence of Multiple Drug Resistant Tuberculosis

    by M. F. Gubkina, I. Yu. Petrakova, M. A. Bagirov, N. V. Yukhimenko, Yu. Yu. Khokhlova, S. S. Sterlikova, Ю. Ю. Хохлова

    The objective: to develop differentiated approaches to the choice of timing of surgical treatment of intrathoracic lymph node tuberculosis (ITLNTB) in children during the increasing incidence of multiple drug resistant tuberculosis (MDR-TB).Subjects and Methods. 52 patients of 2-12 years old had their intrathoracic lymph nodes removed at different stages of anti-tuberculosis therapy. All children had massive (more than 10-15 mm) conglomerates in their intrathoracic lymph nodes. Additionally to changes in intrathoracic lymph nodes, 12 people had active tuberculous changes in the lungs or bronchial tuberculosis.Results. 5 patients were operated before chemotherapy, 35 patients after 2 months of treatment, and 12 patients underwent surgery afterwards. The elective surgery was performed in 51 children, and 1 child had surgery before the start of chemotherapy due to vital indications (the threat of breakthrough of caseous masses into the trachea).Planned surgical treatment in children with tuberculosis of intrathoracic lymph nodes should be carried out within the following timing: before the start of anti-tuberculosis therapy in the absence of clinical, laboratory and radiological signs of the disease being active; as soon as possible from the start of chemotherapy (it is enough to focus on the results of the first CT control after 2 months of treatment (there should be no tendency to involution of pathological changes) in the presence of minimal signs of tuberculosis activity). The choice of timing of planned surgical treatment is individual and determined by the timing of stabilization of pulmonary changes or the cure of bronchial tuberculosis (after 6, 9, 12 months) in patients with newly diagnosed active tuberculosis of intrathoracic lymph nodes in combination with lung and/or bronchial lesions. The development of life-threatening complications is an absolute indication for emergency surgery.